Medivolve Inc MEDVF

Questcap diverse approach going to pay off end of the Day

[Sarb99]

• Rather than developing QuestCap own test kits, they form a partnership. Rather than asking labs to sell QuestCap testing kits, they opened their own covid-19 testing centres. QuestCap does not need to buy any building or invest on lab equipment or accessories. Buy as many testing kits as the needs and can sell. Setup mobile testing centres in the pharmacy, schools, Shopping centres, stadiums, or any other place where they can sell. If one place does not get needed crowd, then move somewhere else, place with demand.

 

• If Abbott Saliva test are cheap, no problem, those tests should be done in a lab according to FDA approval. Start offering lab service for Abbott test. Then charge $25-$35 for lab service to offer Abbott $5 test. QuestCap still make same amount of money. QuestCap does not lose anything, start offering all kind of covid-19 testing. Lyher antibody, Abbott $5 test, Antigen test and take a cut. If they can sell $4 test in Columbia that mean they can compete with Abbott or anyone else.

• QuestCap invested $1 million on Dr. Samira Mubareka top scientists from Sunnybrook Hospital Ontario. Samira Mubareka is one of the scientists advising Canadian GOVT as member of Therapeutics Task Force science advisors. https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01780.html So, she has all kind of links to the GOVT, other scientists, hospitals, and doctors. Same for other investment in Gingras Lab - Lunenfeld-Tanenbaum Research Institute from  Mount Sinai Hospital, they already published 2 studies https://stockhouse.com/companies/bullboard?symbol=v.cuo&postid=31450681 and working on robotic testing platform that can perform 10,000 sample per day  https://www.thestar.com/news/gta/2020/08/10/can-researchers-find-a-way-to-run-10000-covid-19-tests-at-once-a-team-in-toronto-is-trying.html

• Spectral has already received Institutional Review Board (IRB) approval for the clinical study and the principal investigator for the first phase 1 clinical study has been initiated. Once Spectral receives approval to treat under the PIND application it will begin enrolment for the human clinical study immediately.

• Amino Therapeutics is currently focused on developing biologic therapeutics for COVID-19. Amino’s research targets small molecule drug candidates and targeted drug delivery systems to transport biologics into the cytosol.

 

• QuestCap invested in Glenco Medical Corp for long term revenue. QuestCap invested for 28% interest in Columbian Medical clinical, short term as they are busy doing covid-19 testing and long-term planning to open 3 more medical service centres.